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Abstract 
Parkinson’s Disease is a neurodegenerative disease that impacts the activities of daily 
life. Exercise has been determined to be beneficial for individuals diagnosed with Parkinson’s 
disease. In studying the mechanisms at play, animal models are frequently used. One such 
model involves administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to 
induce neurodegeneration in mice. Many studies have investigated how exercise in MPTP-
induced mouse models provide a protective and restorative effect. Often these studies lack 
strong reasoning for the exercise protocol used. This review analyzed many of these studies on 
the basis of exercise duration, intensity, and methodology of MPTP induction to examine their 
effect on various biomarkers associated with Parkinson’s disease in an attempt to determine 
the exercise protocol that could most optimally reduce and provide relief from the diseased 
state.  
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Introduction 
 Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder, 
following Alzheimer’s disease. Between two and three percent of adults over 65 are affected by 
PD. This disease is characterized by a decrease in dopamine resulting from neuronal loss in the 
substantia nigra (SN), reductions in nerve terminals that lead from the SN to the striatum (STR), 
changes in striatal dopaminergic uptake and signaling, and also the accumulation of 
intracellular alpha-synuclein. (Hood et al., 2016; Poewe et al., 2017). The pathogenesis of PD is 
complicated and involves many pathways and mechanisms overall. Primarily, this includes 
alpha-synuclein proteostasis, mitochondrial dysfunction, oxidative stress, calcium homeostasis, 
and neuroinflammation (Poewe et al., 2017). Often diagnoses of PD do not occur until a 
reduction of nearly 70% of dopaminergic neurons of the SN has occurred, at which point PD 
symptoms become increasingly evident (Gerecke et al., 2010; Harrington et al., 1996). Currently 
no therapeutic options exist to prevent PD or slow its progression; current treatments only 
apply to the management of associated symptoms. Exercise, however, is strongly 
recommended to help reduce the symptoms experienced by PD patients. This review will 
examine the potential neuroprotective and neurorestorative benefits that exercise might 
provide in the context of PD. 
 
Background of Literature 
 Animal models of PD are of great importance as they allow for an increased 
understanding of underlying mechanisms and potential therapeutic options. There are four 
primary models used for PD induction in animals. The 6-hydroxydopamine (6-OHDA) model is 
commonly used in rats, and produces a biochemical destruction of the nigrostriatal pathway 
(Crowley et al., 2019). Another model and relatively new, AAV alpha-synuclein, replicates PD by 
overexpression of the alpha-synuclein protein. Further models include the Rotenone and the 1-
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methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). These are utilized for their similarities to 
the progressive neurodegeneration seen in PD via the use of neurotoxins, with the MPTP 
commonly used to model the motor symptoms associated with PD. This review will focus 
largely on the MPTP model. Focusing specifically on this one model allows for greater 
distinction regarding the changes to associated biomarkers since differences associated with 
varying toxins is not present. In addition, the range of animals used with the MPTP model is 
limited as this model is primarily used with studies involving mice. MPTP induces its effect via 
its neurotoxin metabolite, 1-methyl-4-phenylpyridine (MPP+). MPP+ is taken into dopaminergic 
neurons of the SN via the dopamine transporter (DAT), where it acts by blocking and inhibiting 
mitochondrial activity and therefore causing neuronal degeneration and resultant motor 
dysfunction (Crowley et al 2019). The studies reviewed used MPTP administration to model PD. 
Three different methodologies were used: acute, progressive, and chronic. In the acute model 
MPTP was administered at a dosage typically around 20 mg per kg body weight 4-5 times over 
the course of a few days. The progressive model used a dosage that increased from start to 
finish and overlapped with the start of the exercise protocol. Dosing in this method typical 
increased from about 8 mg/kg to 32 mg/kg and was given 5 times per week for 4 about weeks. 
Chronic administration was the third and final model used. In this MPTP model, probenecid was 
used as an adjuvant. Probenecid inhibits clearance of the MPTP neurotoxin and therefore 
causes a rapid loss of dopaminergic neurons. This effect is responsible for more long-term 
neurological and behavioral deficiencies that are not as easily restored months after treatment, 
contrasting acute models that exhibit restoration following excretion of the toxin (Koo et al., 
2017; Lau et al., 2011). 
 Evidence has indicated that physical exercise corresponds with neurodegenerative 
improvements. Multiple human studies have shown that regular exercise as a young adult 
yields a reduced risk of the development of PD decades later. In addition to reducing the risk of 
a PD diagnosis, recent studies have shown that exercise plays a role in the restoration of motor 
function as well as the reduction of non-motor symptoms in individuals affected by PD. Human 
studies have observed improved physical performance in regard to increased speed, gait 
initiation, stride length, muscle strength, balance, and a reduction of falls. These improvements 
observed in human studies are suggested to be associated with increased gray matter volume, 
improved cortico-motor excitability, increased striatal dopamine receptor density, and 
enhanced dopamine levels as a product of exercise. Non-motor symptoms that show 
improvement through exercise include increases in attention and working memory that are 
associated with a rise in cognitive function, enhanced executive function, language, and mood. 
Human studies have provided evidence that exercise not only increases longevity but also 
results in establishing a higher quality of life in individuals confronted with PD. The use of 
animal models, especially rodents, provides a deeper, more mechanistic evaluation of this 
disease, something human studies often lack. Animal studies have provided support for the 
neuroprotective and neurorestorative benefits of exercise, which focus on mechanisms 
involving neurogenesis, neurotrophic factors, neuroinflammation, and oxidative stress (Crowley 
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et al., 2019). Improved motor performance is commonly observed when exercise is applied to 
these models (Figure 1). 
 
 
Figure 1. The effect of treadmill exercise on motor balance and coordination, assessed by Rotarod test. The latency was the 
amount of time required for a mouse to fall from the rod. Performance with increasing speed is graphed above. (From Shin et 
al., 2016). 
Many rodent models of PD, including MPTP models, appear to place minor emphasis on 
the exercise protocol used in experimental studies. High variance exists between exercise type, 
regularity, intensity, and session duration in many protocols. This review will examine various 
exercise protocols used in MPTP administered mouse models and the benefits that coincide 
with exercise as they relate to PD. Neuroprotective and neurorestorative aspects of exercise 
will be evaluated, determined by MPTP induction occurring before or after exercise, 
respectively. Analysis of exercise protocols will be completed to determine the most effective 
methodology used in combatting MPTP induced PD in mice models. 
For determination of exercise protocol effectiveness, the specific markers evaluated 
must be understood, especially in regard to their relationship between diseased and non-
diseased states. Measurement of tyrosine hydroxylase (TH) expression is frequently of interest 
in PD studies. TH is the rate-limiting enzyme responsible for catalyzing the hydroxylation of 
tyrosine to L-DOPA in the synthesis of catecholamines, including dopamine (DA) (Daubner et al., 
2011) (Figure 2). Mouse plasma DA levels exhibit limited sensitivity to measurement, therefore 
TH analysis allows for an alternative way to evaluate the availability of DA (Jang et al., 2017). 
With PD, both TH and DA levels are decreased in the brain, especially in the SN and STR, with 
decreased TH a direct result of dopaminergic neuron loss (Daubner et al., 2011; Shin et al., 
2016; Sung et al.; 2012). Brain-derived neurotrophic factor levels (BDNF) are often measured, 
and are involved in synaptic plasticity, memory, and learning (Sung 2015). The interaction of 
BDNF and its receptor, tyrosine kinase B (Trk B), results in increased neuronal survival and 
differentiation, increased plasticity, improved cognition, decreased free radical production, and 
reduced apoptosis (Gerecke et al., 2012; Sung 2015). In the diseased state, a 70% reduction 
BDNF expression in the SN has been demonstrated (Howells et al., 2000). In general, exercise 
increases expression of BDNF.   
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Figure 2. The pathway of dopamine and the role of synaptic molecules, including tyrosine hydroxylase (TH). (From Bravo et al., 
2014) 
 
Another important marker is the dopamine transporter (DAT), which is responsible for 
reuptake of DA into pre-synaptic nerve terminals, thus regulating DA transmission (Harrington 
et al., 1996). Decreased DAT expression accompanies PD (Hood et al., 2016). Expression of the 
synaptic vesicle amine transporter (VMAT) is also reduced in PD. VMAT is responsible for 
repackaging monoamines into synaptic vesicles (Harrington et al., 1996). Additionally, ionized 
calcium binding adaptor molecule 1 (IBA-1) is involved in facilitating phagocytosis by microglia 
and therefore IBA-1 expression indicates microglia activation (Ohsawa 2004). Increased IBA-1, 
associated with increased alpha-synuclein, is observed in PD (Su et al., 2008). Alpha-synuclein is 
highly involved in PD, although it’s full function is not quite clear. It has been shown to bind to 
TH and reduce the phosphorylation of TH, which as a result, reduces the production of 
dopamine (Daubner et al., 2011). Additionally, alpha-synuclein is suggested to play an early role 
in PD development through its role in inflammation, especially regarding proinflammatory 
molecules such as TNF alpha and IL-beta (Su et al., 2008).  
The synaptic proteins PSD-95 and synaptophysin exhibit decreased expression in PD and in 
MPTP models, as well as a related decrease in dendritic spine density. PSD-95 is located post-
synaptically and is involved in the regulation of synaptic strength and plasticity. Synaptophysin 
is an integral membrane protein of presynaptic vesicles and is often used to indicate synaptic 
density. A decreased level of these two proteins corresponds with decreased synaptic 
transmissions and decreased plasticity (Shin et al., 2016). A decrease in dendritic spine density 
is associated with PD and this loss often occurs as a result of a loss of dopaminergic neurons 
(Toy et al., 2014). Overall, many markers for PD are known, and administration of MPTP in 
mouse models is able to replicate many of these changes.  
Animal studies have indicated that brain neurotrophic factors, especially BDNF and GDNF, 
play an important role in promoting the survival of adult neurons and facilitate processes 
involved in neuroprotection from exercise (Lau et al., 2011). BDNF and GDNF are active in the 
regulation of a signaling cascade that impacts TH transcription, and therefore necessary for 
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dopamine synthesis. (da Silva et al., 2016).  Both BDNF and GDNF have been shown to increase 
following exercise, particularly in both the substantia nigra and striatum (Lau et al., 2011). 
Overall, these two neurotrophic factors, upregulated through exercise, are involved in 
dopaminergic survival and differentiation, inhibition of microglia activation, and neuroplasticity 
and as a result improve motor function (da Silva et al., 2016). Therefore BDNF and GDNF appear 
to have a strong role in neuroprotection when it comes to PD. 
Studies have detailed the rise of many other markers through exercise. Animal models have 
shown that exercise improves mitochondrial respiration, improves ATP function, and maintains 
antioxidant SOD levels (Lau et al., 2011). Additionally, exercise leads to an upregulation of 
antioxidant enzymes and increased activity of mitochondrial enzymes while decreases oxidative 
stress markers (Marques-Alexio et al., 2012).  Anti-inflammatory effects have also been 
observed with exercise in animal models, suggesting a role for exercise to attenuate 
neuroinflammation (Crowley et al., 2019). A benefit such as this would help reduce oxidative 
stress and other negative deficits associated with inflammatory processes, which can be 
especially harmful for cognition. Suppressed inflammation can be seen by a reduction in TNF-
alpha and IL-1beta following exercise (Jang et. al., 2017). Furthermore, exercise is suggested to 
lower reactive oxygen species and improve mitochondrial function (Lau et al., 2011), which is 
necessary to help prevent the accumulation of alpha-synuclein via reactive oxygen species, 
which leads to dopaminergic neuron death. In the context of PD, evidence has shown that 
exercise has a neurorestorative effect in the way it restores motor recovery (Jang et al., 2017).  
 
Methods for Literature Analysis 
 An initial search involved exercise protocols in rodent models of PD. This soon was 
narrowed down to specifically focus on MPTP models of PD, and therefore mice models. 
 Data from selected articles was obtained and entered into an Excel document. When 
available, raw data was used and the percent change compared to the control group (C) was 
determined for the MPTP induced non-exercised group (M) and the MPTP plus exercise group 
(ME). In cases when numerical data was not given, approximations were made from published 
graphical results. For purposes of this review, the control group used to compare M and ME 
was that of a sedentary, non-MPTP induced model group. This data was used to design the 
graphs. Studies that measured similar biomarkers, such as TH and synaptic proteins, were used 
for comparisons. Furthermore, studies were compared that were at the two extremes based on 
treadmill intensity. Data was also used graph was constructed using data that compared results 
when eight weeks of additional exercise was conducted. The biomarkers most common to the 
largest amount of studies, TH and synaptic protein expression, were used to compare results. 
(See Appendix for additional biomarker data and complete table). 
 Ten studies from the 20 total were selected for more direction comparison. This was 
based on characteristic intensities and duration of the exercise protocols used in the study. 
Also, these studies measured similar biomarkers, which allowed for closer comparisons to be 
made based on the type of exercise protocol used. 
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Neuroprotective effects were categorized by basis of MPTP administration at the 
conclusion of exercise protocols. Administration following exercise is indicative of how exercise 
primes the body against toxin-induced neurodegeneration. Neurorestorative effects were 
categorized as MPTP administration that occurred prior to the start of exercise. Studies such as 
these, of which were more predominant, observed how exercise while under the influence of 
the diseased state can allow for improved function overall. The data from these studies was 
then used to determine the type of exercise protocols that provided the most benefit in 
counteracting the diseased state.  
 
 
Table 1. Summary table of s10 selected studies. These studies were used most directly in the graphical analysis described in this 
review. They were based on their time of MPTP administration, intensity, length of protocol, and biomarkers measured.   
 
Results 
 
Neuroprotection 
Voluntary wheel running before MPTP administration protected dopaminergic neurons 
from MPTP induced cell death (Figure 3). This protective effect was observed to the greatest 
extent when mice exercised for 3 months prior to MPTP administration. No protection occurred 
when mice only exercised for one-month prior. Additionally, mice that were allowed to 
voluntarily run the greatest set distance at 7.5 km per day were protected the most from 
neuronal loss. In the case where the running wheel was locked once a specified distance was hit 
(2.4 and 4.8 km per day), mice in these groups received less protective benefits and therefore 
were more vulnerable to neuronal loss when MPTP was administered using an acute model. 
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Figure 3.  
A) Voluntary wheel running and its protective effect on dopaminergic neurons at durations of 1, 2, and 3 months prior to MPTP 
administration. B) The protective effect of voluntary wheel running when daily distance ran was controlled. Mice were allowed 
to run for 2.5, 4.8, or 7.5 km per day for three months prior to MPTP administration. (From Gerecke et al., 2010) 
 
Neurorestoration 
Comparisons of a low intensity, 8 m/min (Shin et al., 2016) with a high intensity, 24 
m/min (Toy et al., 2014) exercise protocol provided a distinct advantage for higher intensity 
exercise (Figure 4). The average amount of recovery from the high intensity exercise protocol 
was almost twice that of the less intense protocol, with an average of 16% more recovery 
across the three markers measured.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 4. Summary of comparison of acute high intensity to low intensity exercise on biomarker recovery.  
 
Measurement of SN and STR TH expression by way of optical density was a common technique 
used in multiple studies. Mice models showed a fair amount of variability in TH expression 
recovery when exercised (Figure 5). The majority of these studies displayed a recovery effect 
that was near 20%. However, two studies did show that exercise reduced the potential for TH 
recovery. On average, a recovery of 20.5% of TH in the SN was observed, while striatal TH 
recovery averaged 19% compared to the non-exercised MPTP models.  
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Figure 5. Summary of TH recovery. TH was determined via optical density and compared in the SN and STR. 
 
In a chronic MPTP model, the duration of the exercise protocol had a large impact on the 
associated benefits (Figure 6). In both 10 week at 18 week studies conducted by Lau et al. 
(2011) exercise provided recovery in multiple parameters. Recovery as a result of exercise 
following MPTP administration was substantially greater in mice that exercised for a total of 18 
weeks versus 10 weeks when both were compared to MPTP non-exercised group. The mice 
exposed to 18 weeks of exercise showed nearly a 4-fold increase in recovery when compared to 
the mice that exercised for 8 weeks less. In this study the intensity remained the same, which 
provides support for importance of exercise of an extended period of time.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Comparison of exercise durations upon PD biomarker recovery at constant intensity. (Lau et al., 2011) 
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The method of MPTP administration used played a role in the amount of recovery that was 
possible with exercise. While recovery from MPTP administration occurred in all models, the 
acute and chronic PD models allowed for a greater extent of recovery compared to the 
progressive models. The average percent of recovery of SN TH and STR TH for studies involving 
each model was compared (Figure 7). The acute model averaged a 22% recovery of TH 
combined between the SN and STR, and the chronic averaged a 29.5% recovery. The 
progressive model showed the least amount of possible restoration, with an average TH 
recovery of 8.5%. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Comparisons of MPTP administration methods related to TH recovery from exercise. 
 
Discussion 
 The protective effects of exercise prior to MPTP administration were most noticeable 
when mice were allowed to run for a full 3 months prior combined with the greatest total daily 
distance of 7.5 km. Protocols that were shortened by one or two months provide less 
protection. Similarly protocols that limited the mice to 2.4 km or 4.8 km per day maximum saw 
less protection from the loss of dopaminergic neurons. This highlights the combined 
importance of both intensity and length of exercise for most optimal results, and indicates that 
in an acute model of PD, exercise exhibits preventative measures. Showing that exercise exerts 
a protective results suggests that exercise has the potential to minimize neuronal loss in 
individual who may be susceptible to PD.  
 Of the selected forced treadmill studies, Shin et al. (2016) was the least intensive at 8 
m/min, while Toy et al. (2014) was the most intensive, with an intensity that started at 10 
m/min and increased to 24 m/min as the exercised mice became more conditioned. These 
studies both focused on measurements that involved dendritic spine density and the synaptic 
protein markers PSD-95 and synaptophysin. Mice in the more intensive exercise study however 
had 10 additional days of exercise compared to the low intensity study. Both studies showed 
that exercise was successful in attenuating biomarker changes that followed MPTP 
administration, although the more intensive study, Toy et al. (2014) provided a noticeably 
greater amount of biomarker recovery in each of the three categories. This provides support for 
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higher intensity exercise having an increased restorative effect following MPTP administration. 
As evident with these studies, the restorative effect was seen with recovered levels of synaptic 
proteins and dendritic spine densities. An increase in these markers close to the control level of 
expression is associated with improved synaptic transmission and synaptic plasticity (Shin et al., 
2016). 
 Six of the selected studies were graphed according to the percent of TH loss that was 
attenuated when exercise was applied to the MPTP model. Two of the studies saw a lack of TH 
recovery; one with a lack of SN TH recovery and the other involving a lack of STR TH recovery. 
Apart from these two results, the majority of the studies indicated varying degrees of recovery 
in both the substantia nigra and striatum (Koo et al., 2016 did not measure STR TH). This 
provides evidence for exercise’s restorative effects, although a range of variation exists. 
 The study conducted by Lau et al., (2011) was unique among those selected based on 
how exercise and MPTP administration were applied. In this protocol, forced treadmill exercise 
began 1 week prior to MPTP administration. MPTP was administered every 3.5 days for 5 
weeks, during which treadmill exercise continued. Following the completion of MPTP 
administration, 12 additional weeks of exercise was completed, for a total of 18 weeks. A much-
reduced impairment was observed in the extended, 18 weeks of exercise compared to 10 
weeks. Reduced impairments involving the number of SN TH positive neurons, SN and STR TH 
optical densities, and STR dopamine contents were all observed in the longer exercised mice. 
This helps clarify the importance of exercise duration. A more prolonged period of exercise was 
noticeably more beneficial in this case, and provides support frequent, regular exercise for 
patients with PD. 
 Overall, exercise was beneficial it counteracting the negative effects of MPTP 
administration. The degree of effectiveness and the types of improvements that were made 
varied. Most studies did see behavioral improvements following exercise such as increased 
Rotarod and Beam test performance. More variability existed in regard to the biological 
markers. In many instances exercise had a beneficial effect, although the extent of this effect 
was not always clearly evident, and a few showed worsening of biomarkers. Following analysis 
of these studies, the importance of the MPTP administration protocol plays a serious role in the 
amount of benefit that can be seen with exercise, particularly regarding the measurement of 
biological markers, which is likely due to the amount of overall dopaminergic cell death caused. 
Acute, progressive and chronic models of PD were used in these studies based on the MPTP 
administration process. Different types of administration were used to for the study of specific 
characterizations of this disease, although clarity regarding the amount of neurodegeneration 
desired in the models was often vague. Based on the data from exercised groups from each of 
these studies, it appears that there becomes a point when the benefits of exercise decrease. In 
the progressive model, which increased dosage of toxin on a weekly basis, only a minimal 
amount of recovery, on average, was observed. This could highlight the potential for there to 
be a most optimal window corresponding to a percentage of remaining dopaminergic neurons. 
Once too much loss has occurred, the benefits of exercise may cease. Such a possibility 
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provides even more reason for exercise to be an important aspect of daily life for both non-PD 
individuals and those with the disease. 
Overall, exercise protocols that maintained relative similarity showed that longer-term 
exercises were more beneficial to shorter exercise protocols. This was particularly clear 
regarding the potential neuroprotective effects of exercise prior to MPTP administration, as 
seen in Gerecke et al. (2010). Improvements were also observed related to increased exercise 
longevity when exercise was intimated following the loss of dopaminergic neurons as seen in 
Lau et al. (2011) when more benefits arose when the exercise protocol was extended by 8 
weeks. When considering intensity, the more intense protocols, determined by treadmill speed, 
resulted in greater beneficial effects compared to lower intensity exercise, although benefits 
existed in both scenarios.  
 Moving forward, exercise protocols in MPTP studies must take into serious 
consideration the process and amount of MPTP administration used. This appears to be the 
influential factor in determining the type of benefits that exercise can provide in counteracting 
the diseased state. This does correspond to the pathogenesis of PD; as individuals with PD age, 
their ability for exercise will be reduced, and from the analysis of these studies it would suggest 
that the as PD progresses the benefits associated with exercise decrease as well. This would 
support evidence that shows that regular exercise in early adulthood is helps reduce the 
occurrence of PD later in life, as this is a time period when exercise could be most optimally 
effective in individuals. In regard to mouse models, protocols should attempt to reach a 
reasonably high intensity. One way to accomplish this is through weekly increases in treadmill 
speed, similar to what was employed by Toy et al. (2014). Here, researchers increased treadmill 
speed so that mice were in a forward position on the treadmill for 75% of the daily exercise 
period. Because of this standard, treadmill intensities were able to increase weekly as the level 
of performance increased. For mouse models that want the greatest possible recovery from 
MPTP toxicity, protocols that focus on high intensity for several months are most applicable. 
Further research focusing on animal models should strongly consider the utilization of newer 
PD models that more closely replicate the symptoms and pathogenesis of this disease. Such 
models would allow for a more applicable comparison that would provide more useful insight 
overall, in addition to looking at exercise related benefits. The analysis of mouse model MPTP 
studies in this review has supported existing evidence that not only is exercise critical for health 
overall, but that it can alleviate some of the negative consequences that arise with Parkinson’s 
disease, and therefore lead an overall increased quality of life for individuals faced with this 
challenging disease. 
 High intensity, long duration exercise protocols were found to be the most effective in 
this review. High intensity and longer duration exercise showed the greatest recovery in the 
biomarkers examined in this review. This finding, however, raises an issue with the viability of 
such exercise in PD patients. When decreased motor function is present, the ability to 
participate in a high intensity workout is likely to be heavily impaired. Based on the data 
collected in this review, if an individual is unable to reach an ideal intensity during exercise, the 
duration of the exercise could be increased in order to maximize the potential health benefits. 
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Cycling on a stationary bike would be optimal for this scenario. Intensity and duration could be 
manipulated, and the balance issues associated with PD would negate. Research has shown 
cycling to be beneficial in PD patients, specifically when done in an instructor led group. In such 
a group an instructor is partly responsible for the overall intensity, and individuals who 
exercised in the group were able to maintain a greater intensity than those who exercised 
individually (McGough et al., 2016). For individuals who found difficulty in reaching a specified 
intensity, increasing the duration could be an alternative method for optimal benefits, as 
suggested by the data collected here in this review. Future considerations should look at 
additional exercise types, focusing both on intensity and duration. Additionally, investigating 
the effects of intensity and duration directly on exercises such as cycling, boxing, and swimming 
could provide beneficial feedback for individuals who want to incorporate this as part of their 
PD treatment. Having a scientifically backed approach for substituting intensity for duration and 
vice-versa could provide encouraging and necessary motivation for PD patients to pursue 
regular exercise. Incorporating frequent exercise is an important aspect for improving the lives 
of individuals living with PD and should be of serious focus for treatment plans.
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Appendix 
 
Source 
Exercise 
Type 
Dose Mice 
Exercise occur 
pre or post 
administration 
Max 
Intensity 
Time per 
session 
Total days Results 
Faherty 2005 Voluntary WR 20mg/kg every 2h x4 Aged; F Pre - - 7d 
SN TH positive neurons: ME attenuated loss by 38% 
SN BDNF mRNA expression: ME attenuated loss by 28% 
SN GDNF mRNA expression: ME attenuated loss by 46% 
SN DAT mRNA expression: ME attenuated loss by 17% 
SN VMAT2 mRNA expression: ME attenuated loss by 20% 
Gerecke 2010 Voluntary WR 20mg/kg x4 every 2h Adult; F Pre - - 90d 
1 mo unrestricted exercise: ↓ 41.5%  TH positive neurons in SN 
2 mo unrestricted exercise: ↓ 16.6% vs. M 
3 mo unrestricted exercise: ↓ 9.2% vs. M 
3 mo at 2.4 km/day: ↓ 35.6% in TH positive neurons in SN 
3 mo at 4.8 km/day: ↓ 30.7% vs. M 
3 mo at 7.5 km/day: fully protected vs. M 
STR DA: ME attenuated loss by 18% 
Gerecke 2012 Voluntary WR 20mg/kg x4 every 2h Adult; F Pre - - 90d 
SN TH positive number: ME attenuated loss by 35% 
SN TH positive number: ME (+/-BDNF) attenuated loss by only 11% 
Klein 2016 Voluntary WR 20mg/kg for 3 days Adult; F Post; 7d - - 
10d 
20d 
STR DA: 10day: ME attenuated loss by 10% 
STR DA: 28day: ME attenuated loss by 10% 
Sconce 2015 Voluntary WR 
8mg/kg incr. to 
32mg/kg 5d/wk for 
4wk 
Adult; M 
Pre; 2wk before start 
of exercise.  
- - 14d 
STR TH (OD): ME attenuated loss by -3% 
SN TH (OD): ME attenuated loss by 14% 
SN VMAT2: ME fully attenuated loss by 41%  
SN DAT (ratio): ME fully attenuated the increased ratio by 71%  
SN VGLUT1: ME attenuated increase by 66% 
SN GLT-1: ME fully attenuated loss by 89%  
Churchill 2017 Forced TM 
8mg/kg incr. to 
32mg/kg 5d/wk for 
4wk 
Adult; M Post; 4wk 10.8 m/min 60 min 20d 
SN TH protein expression (OD): ME attenuated loss by 6% 
STR TH protein expression (OD): ME attenuated loss by 21% 
SN DAT protein expression( OD) ME fully attenuated increase by 170% 
STR DAT protein expression (OD):ME attenuated loss by 45% 
STR BDNF and TRKB: No change 
STR GLT-1 levels: Me increased by 100% 
IBA-1 protein levels in the STR: ME attenuated increase by 200% 
Hood 2016 Forced TM 
6mg/kg incr. to 24 
mg/kg 5d/wk for 4wk 
Aged; M Post; 2 wk 10.8 m/min 60 min 20d 
ME increased spontaneous locomotion 
STR TH (OD): ME attenuated loss by -2% 
STR TH: ME attenuated loss by 0% 
STR DAT: ME attenuated loss by 0% 
STR DA: ME attenuated loss by 0% 
MCtx TH expression: ME attenuated loss by 106% 
Jang 2017 Forced TM 
25mg/kg every 3.5d 
for 5wk 
Adult; M Post; immediately 10 m/min 60 min 40d 
Alpha-synuclein: ME attenuated increase by 18% 
STR TLR2 ME attenuated increase by 55% 
STR TNFalpha: ME fully attenuated increase by 30% 
STR IL-1beta: ME attenuated increase by 50% 
STR apoptotic cell death: ME fully attenuated increased by 200% 
STR TH protein: ME attenuated loss by 25% 
SN TH protein: ME attenuated loss by 20% 
SN TH positive neurons: ME attenuated loss by 50% 
Koo 2017 Forced TM 
25mg/kg every 3.5d 
for 5wk 
Adult; M Post; immediately 12 m/min 60 min 40d 
ME: ↑ in retention time on Rotarod 
TH protein in SN: ME attenuated loss by 30% 
DAT protein in the SN: ME attenuated loss by 30% 
SN number of TH positive cells: ME attenuated loss by 30% 
Alpha-syn expression in SN: ME attenuated increase by 70% 
Alpha-syn expression in STR: ME attenuated increase by 55%  
Bcl-2 protein in SN: ME attenuated loss by 25% 
Bax protein in SN: ME attenuated loss by 120% 
cleaved capase 3 protein in SN: ME attenuated increase by 55% 
SN MIM proteins TOM-40 (ME attenuated loss by 50%)  
TOM-20 (ME attenuated loss by 45%)  
TIM-23 (ME attenuated loss by 20%) 
SN COX-1 protein (ME attenuated loss by 35%) 
COX-IV protein (ME attenuated loss by 35%) 
mtHSP70 protein (ME attenuated loss by 20%) 
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Lau 2011 Forced TM 
15mg/kg every 3.5d 
for 5 wk 
Adult; M 
1 wk prior; 5 wk 
during; 12 week post 
15m/min 40 min 90d 
Number of SN TH-positive neurons: ME attenuated loss by 49%SN TH 
(OD): ME attenuated loss by 41%STR TH (OD): ME attenuated loss by 
50.6%STR DA: ME attenuated loss by 25%STR DAT: (OD) ME 
attenuated loss by 20%Beam Test Performance: ME attenuated slips 
by 11%STR Carbonylated proteins: ME attenuated increase by 14%Mn 
SOD (STR antioxidant enzyme): ME attenuated loss by 31%Cu-Zn SOD 
(STR antioxidant enzyme): ME attenuated loss by 22%BDNF in SN: ME 
increased by 50%; no change in STRGDNF in STR ME increased by 79%; 
no change in SN 
Patki 2011 Forced TM 
15mg/kg every 3.5d 
for 5 wk 
Adult; M 
1 wk prior; 5 wk 
during; 12 week post 
15m/min 40 min 90d 
STR cytochrome C: ME attenuated loss by 20% 
STR mRNA of p53: ME attenuated increase by 20 
STR mRNA of TFAM: ME attenuated increase by 226% 
STR mRNA of PGC-1alpha: ME attenuated increase by 33% 
Shin 2016 Forced TM 20mg/kg x4 every 2h Adult; M Post; 1d 8 m/min 30 min 28d 
Rotarod performance: ME attenuated loss by 90% 
SN TH+ SN: ME attenuated loss by 23% 
STR TH positive fibers (OD): ME attenuated loss by 7% 
STR PSD-95 protein: ME attenuated loss by 18% 
STR synaptophysin protein: ME attenuated loss by 11% 
STR dendritic spine density: ME attenuated loss by 24% 
Smith 2011 Forced TM 30mg/kg for 7d Adult; M Post; 1d 10.8 m/min 60 min 19d 
ME: ↑ physical ability and improved gait performance  
SN TH + cells: ME attenuated loss by 21% 
SN Thionin stained cells: ME attenuated loss by 15% 
STR TH (OD): ME attenuated loss by 19% 
STR DAT (OD): ME attenuated loss by 23% 
Sung 2015 Forced TM 
25mg/kg every 3.5d 
for 5wk 
Adult; M Post; 1d 10 m/min 30 min 20d 
ME: ↑ latency in passive avoidance test 
SN TH protein: ME attenuated loss by 39% 
SN D2DR protein: ME attenuated loss by 16% 
SN BDNF: ME attenuated loss by 13% 
SN Trk B: ME attenuated loss by 19% 
ME: restored BrdU/DCX positive cells and BrdU/NeuN positive cells in 
the hippocampus to control levels. 
Tillerson Forced TM 2x 15mg/kg for 1d Aged; M Post; 12hours 5 m/min 5x2 min 9d 
STR TH: ME attenuated loss by 21% 
STR VMAT2: ME attenuated loss by 12% 
STR DAT: ME attenuated loss by 15% 
Toy 2014 Forced TM 20mg/kg x4 every 2h Adult; M Post; 5d 24 m/min 30x2 min 30d 
ME mice able to achieve running velocity that was not different from 
that of controls after 5 weeks of treadmill exercise 
Exercise overall ↑ spine density vs. non exercised; 
STR DA: No recovery 
STR dendritic spine density: ME attenuated loss by 34% 
STR PSD-95 synaptic protein ME attenuated loss by 33% 
STR synaptophysin synaptic protein: ME attenuated loss by 35% 
Jang 2018 Forced TM 
25mg/kg every day for 
1 wk 
Adult; M Post; 4 wk 12 m/min 60 min 30d 
SN TH positive cell number: ME attenuated loss by 28% 
SN DAT level: ME attenuated loss by 26% 
Fisher 2004 Forced TM 20mg/kg every 2h x4 Adult; M Post; 4 days 23.0 m/min 30x2 min 30d 
Velocity m/min after protocol:  ME attenuated loss by 90% 
STR DAT (optical density): ME attenuated loss by -17% 
STR TH expression (optical density): ME attenuated loss by -27%  
Pothakos 2009 Forced TM 
25mg/kg every 3.5 
days x10 
Aged; M 
1 wk prior; 5 wk 
during; 12 week post 
15 m/min 40 min 90d 
STR DA (ng/mg tissue): ME attenuated loss by 5% 
SN TH positive neurons: No recovery 
Sung 2012 Forced TM 
20mg/kg every 3.5 
days x10 
Adult; M Post; 1d 12 m/min 30 min 20d 
SN TH cell number: ME attenuated loss by 22% 
STR TH fiber density (OD):  ME attenuated loss by 10% 
Rotarod performance: ME attenuated performance loss by 75% 
 
